tbuckley/cabot-search huggingface dataset:
Improving inclusion and well-being of trans and gender nonconforming collegiate student–athletes: foundational concepts from the National Collegiate Athletic Association Summit on Gender Identity and Student–Athlete Participation
Authors: Emily Kroshus, Kathryn E Ackerman, Mac Brown, Pat Griffin, LaGwyn Durden, Jean Merrill, Amy Wilson, Brian Hainline
Journal: British Journal of Sports Medicine (2023)

The National Collegiate Athletic Association (NCAA) Summit on Gender Identity and Student–Athlete Participation was convened to identify institutional/athletic department strategies that may support the well-being of trans and gender nonconforming (TGNC) collegiate student–athletes in the USA. The Summit’s purview did not include policy-level changes to eligibility rules. A modified Delphi consensus process was used to identify strategies for supporting collegiate TGNC student–athlete well-being. Key steps included an exploration phase (learning, generating ideas), and an evaluation phase (rating ideas in terms of their utility and feasibility). Summit participants (n=60) included individuals meeting at least one of the following criteria: current or former TGNC athlete, academic or healthcare professional with topical expertise, collegiate athletics stakeholder who would be involved in implementing potential strategies, representative from leading sports medicine organisation, or representative from relevant NCAA membership committee. Summit participants identified strategies in the following domains: healthcare practices (patient-centred care and culturally sensitive care); education for all stakeholders involved in athletics; and administration (inclusive language, quality improvement processes). Summit participants also proposed ways that the NCAA, through its existing committee and governance structures, could help support the well-being of TGNC athletes. NCAA-focused concepts were in the following domains: policy making processes; eligibility and transfer processes; resource development and dissemination; and visibility and support for TGNC athletes. The strategies developed represent important and relevant approaches that member institutions, athletic departments, NCAA committees, governance bodies and other stakeholders might consider in their efforts to support TGNC student–athlete well-being.
Genome-wide association study identifies genetic variants which predict the response of bone mineral density to teriparatide therapy
Authors: Nerea Alonso, Omar M E Albagha, Asim Azfer, Beatriz Larraz-Prieto, Kathryn Berg, Philip L Riches, Barbara Ostanek, Tomaz Kocjan, Janja Marc, Bente L Langdahl, Stuart H Ralston
Journal: Annals of the Rheumatic Diseases (2023)

Objectives Teriparatide (TPTD) is an effective treatment for osteoporosis but the individual response to therapy is variable for reasons that are unclear. This study aimed to determine whether the response to TPTD might be influenced by genetic factors. Methods We searched for predictors of the response of bone mineral density (BMD) to TPTD using a two-stage genome-wide association study in 437 patients with osteoporosis from three referral centres. Demographic and clinical data including the response of BMD to treatment at the lumbar spine and hip were extracted from the medical records of each participant. Results Allelic variation at rs6430612 on chromosome 2, close to the CXCR4 gene was associated with the response of spine BMD to TPTD at a genome wide significant level (p=9.2×10 −9 beta=−0.35 (−0.47 to −0.23)). The increase in BMD was almost twice as great in AA homozygotes at rs6430612 as compared with GG homozygotes with intermediate values in heterozygotes. The same variant was also associated with response of femoral neck and total hip BMD (p=0.007). An additional locus on chromosome 19 tagged by rs73056959 was associated with the response of femoral neck BMD to TPTD (p=3.5×10 −9 , beta=−1.61 (−2.14 to −1.07)). Conclusions Genetic factors influence the response to TPTD at the lumbar spine and hip with a magnitude of effect that is clinically relevant. Further studies are required to identify the causal genetic variants and underlying mechanisms as well as to explore how genetic testing for these variants might be implemented in clinical practice.
Worsening Spread of <i>Candida auris</i> in the United States, 2019 to 2021
Authors: Meghan Lyman, Kaitlin Forsberg, D. Joseph Sexton, Nancy A. Chow, Shawn R. Lockhart, Brendan R. Jackson, Tom Chiller
Journal: Annals of Internal Medicine (2023)

Background: Candida auris is an emerging fungal threat that has been spreading in the United States since it was first reported in 2016. Objective: To describe recent changes in the U.S. epidemiology of C auris occurring from 2019 to 2021. Design: Description of national surveillance data. Setting: United States. Patients: Persons with any specimen that was positive for C auris. Measurements: Case counts reported to the Centers for Disease Control and Prevention by health departments, volume of colonization screening, and antifungal susceptibility results were aggregated and compared over time and by geographic region. Results: A total of 3270 clinical cases and 7413 screening cases of C auris were reported in the United States through 31 December 2021. The percentage increase in clinical cases grew each year, from a 44% increase in 2019 to a 95% increase in 2021. Colonization screening volume and screening cases increased in 2021 by more than 80% and more than 200%, respectively. From 2019 to 2021, 17 states identified their first C auris case. The number of C auris cases that were resistant to echinocandins in 2021 was about 3 times that in each of the previous 2 years. Limitation: Identification of screening cases depends on screening that is done on the basis of need and available resources. Screening is not conducted uniformly across the United States, so the true burden of C auris cases may be underestimated. Conclusion: C auris cases and transmission have risen in recent years, with a dramatic increase in 2021. The rise in echinocandin-resistant cases and evidence of transmission is particularly concerning because echinocandins are first-line therapy for invasive Candida infections, including C auris. These findings highlight the need for improved detection and infection control practices to prevent spread of C auris. Primary Funding Source: None.
Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial)
Authors: Roger Olofsson Bagge, Axel Nelson, Amir Shafazand, Charlotta All-Eriksson, Christian Cahlin, Nils Elander, Hildur Helgadottir, Jens Folke Kiilgaard, Sara Kinhult, Ingrid Ljuslinder, Jan Mattsson, Magnus Rizell, Malin Sternby Eilard, Gustav J. Ullenhag, Jonas A. Nilsson, Lars Ny, Per Lindnér
Journal: Journal of Clinical Oncology (2023)

About half of patients with metastatic uveal melanoma present with isolated liver metastasis, in whom the median survival is 6-12 months. The few systemic treatment options available only moderately prolong survival. Isolated hepatic perfusion (IHP) with melphalan is a regional treatment option, but prospective efficacy and safety data are lacking.In this multicenter, randomized, open-label, phase III trial, patients with previously untreated isolated liver metastases from uveal melanoma were randomly assigned to receive a one-time treatment with IHP with melphalan or best alternative care (control group). The primary end point was overall survival at 24 months. Here, we report the secondary outcomes of response according to RECIST 1.1 criteria, progression-free survival (PFS), hepatic PFS (hPFS), and safety.Ninety-three patients were randomly assigned, and 87 patients were assigned to either IHP (n = 43) or a control group receiving the investigator's choice of treatment (n = 44). In the control group, 49% received chemotherapy, 39% immune checkpoint inhibitors, and 9% locoregional treatment other than IHP. In an intention-to-treat analysis, the overall response rates (ORRs) were 40% versus 4.5% in the IHP and control groups, respectively (P < .0001). The median PFS was 7.4 months versus 3.3 months (P < .0001), with a hazard ratio of 0.21 (95% CI, 0.12 to 0.36), and the median hPFS was 9.1 months versus 3.3 months (P < .0001), both favoring the IHP arm. There were 11 treatment-related serious adverse events in the IHP group compared with seven in the control group. There was one treatment-related death in the IHP group.IHP treatment resulted in superior ORR, hPFS, and PFS compared with best alternative care in previously untreated patients with isolated liver metastases from primary uveal melanoma.
Trait profiles in difficult‐to‐treat asthma: Clinical impact and response to systematic assessment
Authors: Tiffany Lin, Jonathan Pham, Eve Denton, Joy Lee, Fiona Hore‐Lacy, Asger Sverrild, Stephanie Stojanovic, Tunn Ren Tay, Kavitha Garuna Murthee, Naghmeh Radhakrishna, Monique Dols, Janet Bondarenko, Janine Mahoney, Robyn E. O'Hehir, Eli Dabscheck, Mark Hew
Journal: Allergy (2023)

Multidisciplinary systematic assessment improves outcomes in difficult-to-treat asthma, but without clear response predictors. Using a treatable-traits framework, we stratified patients by trait profile, examining clinical impact and treatment responsiveness to systematic assessment.We performed latent class analysis using 12 traits on difficult-to-treat asthma patients undergoing systematic assessment at our institution. We examined Asthma Control Questionnaire (ACQ-6) and Asthma Quality of Life Questionnaire (AQLQ) scores, FEV1 , exacerbation frequency, and maintenance oral corticosteroid (mOCS) dose, at baseline and following systematic assessment.Among 241 patients, two airway-centric profiles were characterized by early-onset with allergic rhinitis (n = 46) and adult onset with eosinophilia/chronic rhinosinusitis (n = 60), respectively, with minimal comorbid or psychosocial traits; three non-airway-centric profiles exhibited either comorbid (obesity, vocal cord dysfunction, dysfunctional breathing) dominance (n = 51), psychosocial (anxiety, depression, smoking, unemployment) dominance (n = 72), or multi-domain impairment (n = 12). Compared to airway-centric profiles, non-airway-centric profiles had worse baseline ACQ-6 (2.7 vs. 2.2, p < .001) and AQLQ (3.8 vs. 4.5, p < .001) scores. Following systematic assessment, the cohort showed overall improvements across all outcomes. However, airway-centric profiles had more FEV1 improvement (5.6% vs. 2.2% predicted, p < .05) while non-airway-centric profiles trended to greater exacerbation reduction (1.7 vs. 1.0, p = .07); mOCS dose reduction was similar (3.1 mg vs. 3.5 mg, p = .782).Distinct trait profiles in difficult-to-treat asthma are associated with different clinical outcomes and treatment responsiveness to systematic assessment. These findings yield clinical and mechanistic insights into difficult-to-treat asthma, offer a conceptual framework to address disease heterogeneity, and highlight areas responsive to targeted intervention.
Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine–Topiramate to Prevent Exposure During Pregnancy
Authors: Amir Sarayani, William Troy Donahoo, Christian Hampp, Joshua D. Brown, Almut G. Winterstein
Journal: Annals of Internal Medicine (2023)

The U.S. Food and Drug Administration approved phentermine-topiramate for obesity in 2012 and required a Risk Evaluation and Mitigation Strategy (REMS) to prevent prenatal exposure. No such requirement was introduced for topiramate.To evaluate the rate of prenatal exposure, contraceptive use, and pregnancy testing among patients with phentermine-topiramate compared with topiramate or other antiobesity medications (AOMs).Retrospective cohort study.Nationwide health insurance claims database.Females aged 12 to 55 years with no infertility diagnosis or sterilization procedure. Patients with other indications for topiramate were excluded to identify a cohort that was likely treated for obesity.Patients initiated use of phentermine-topiramate, topiramate, or an AOM (liraglutide, lorcaserin, or bupropion-naltrexone). Pregnancy at treatment initiation, conception during treatment, contraceptive use, and pregnancy testing outcomes were ascertained. Measurable confounders were adjusted for, and extensive sensitivity analyses were done.A total of 156 280 treatment episodes were observed. Adjusted prevalence of pregnancy at treatment initiation was 0.9 versus 1.6 per 1000 episodes (prevalence ratio, 0.54 [95% CI, 0.31 to 0.95]) for phentermine-topiramate versus topiramate. The incidence rate of conception during treatment was 9.1 versus 15.0 per 1000 person-years (rate ratio, 0.61 [CI, 0.40 to 0.91]) for phentermine-topiramate versus topiramate. Both outcomes were similarly lower for phentermine-topiramate compared with AOM. Prenatal exposure was marginally lower in topiramate users compared with AOM users. Approximately 20% of patients in all cohorts had at least 50% of treatment days covered by contraceptives. Few patients had pregnancy tests before treatment (≤5%), but this was more common among phentermine-topiramate users.Outcome misclassification; unmeasured confounding due to lack of prescriber data to account for possible clustering and spillover effects.Prenatal exposure seemed to be significantly lower among phentermine-topiramate users under the REMS. Pregnancy testing and contraceptive use appeared to be inadequate for all groups, which deserves attention to prevent the remaining potential exposures.None.
Multifunctional MOF‐Based Microneedle Patch With Synergistic Chemo‐Photodynamic Antibacterial Effect and Sustained Release of Growth Factor for Chronic Wound Healing
Authors: Yongnian Zeng, Chenyuan Wang, Kai Lei, Chuan Xiao, Xue Jiang, Wen Zhang, Lujuan Wu, Jianying Huang, Wei Li
Journal: Advanced Healthcare Materials (2023)

Chronic wound healing is a major challenge in biomedicine. Conventional therapies are usually associated with poor drug permeability, low bioavailability, risk of antimicrobial resistance, and require frequent administration. Therefore, a novel formulation with reduced antibiotic dosage, improved drug delivery efficiency, and low application frequency is of remarkable interest for chronic wound healing. Herein, a multifunctional microneedle (MN) patch is presented to achieve rapid wound healing via efficient chemo-photodynamic antibacterial effect and sustained release of growth factors at the wound bed. When the MN patch pierces the skin, MN tips carrying both low dosage of antibiotics and bioactive small molecule-encapsulated metal-organic frameworks (MOFs) rapidly dissolve and subsequently deliver the payloads to the wound. Upon light irradiation, MOF-based nanoparticles robustly convert O2 into 1 O2 , which acts synergistically with chemotherapy to remove pathogenic bacteria from the wound, exhibiting excellent chemo-photodynamic antibacterial performance with a tenfold reduction in the required antibiotic amount. The nanoparticles can achieve a continuous release of growth factors in the wound tissue, promoting the formation of epithelial tissue and neovascularization, thereby further accelerating chronic wound healing. Collectively, the designed multifunctional MOF-based MN patches offer a simple, safe, and effective alternative for chronic wound management.
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
Authors: Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi
Journal: Clinical and Molecular Hepatology (2023)

Striking advances in systemic therapy for unresectable advanced hepatocellular carcinoma (HCC) have improved the average prognosis of patients with HCC. As a result, the guidelines for the treatment of HCC have changed significantly. However, various issues have emerged in clinical practice. First, there is no established biomarker that can predict response to systemic therapy. Second, there is no established treatment regimen after primary systemic therapy, including combined immunotherapy. Third, there is no established treatment regimen for intermediate-stage HCC. These points make the current guidelines ambiguous. In this review, we present the Japanese guidelines for the diagnosis and treatment of HCC based on the latest evidence; introduce various efforts mainly in Japanese real-life practice to update these guidelines; and present our perspectives on future guidelines.
Influence of Culprit Lesion Intervention on Outcomes in Infarct-Related Cardiogenic Shock With Cardiac Arrest
Authors: Uwe Zeymer, Brunilda Alushi, Marko Noc, Mamas A. Mamas, Gilles Montalescot, Georg Fuernau, Kurt Huber, Janine Poess, Suzanne de Waha-Thiele, Steffen Schneider, Taoufik Ouarrak, Steffen Desch, Alexander Lauten, Holger Thiele
Journal: Journal of the American College of Cardiology (2023)
Changes in Cardiorespiratory Fitness and Survival in Patients With or Without Cardiovascular Disease
Authors: Peter Kokkinos, Charles Faselis, Immanuel Babu Henry Samuel, Carl J. Lavie, Jiajia Zhang, Jose D. Vargas, Andreas Pittaras, Michael Doumas, Pamela Karasik, Hans Moore, Michael Heimal, Jonathan Myers
Journal: Journal of the American College of Cardiology (2023)
Representation of Women and Minority Faculty and Fellows in Academic Pediatric Cardiology Training Programs
Authors: Sowmya Balasubramanian, Sara K. Pasquali, Melissa K. Cousino, Ray E. Lowery, Andrea S. Les, Sunkyung Yu, Amanda D. McCormick, Caroline L. West, Carlen G. Fifer, Caren S. Goldberg, Jennifer C. Romano, Sonal T. Owens
Journal: Journal of the American College of Cardiology (2023)
Association of Incident Cardiovascular Disease With Time Course and Cumulative Exposure to Multiple Risk Factors
Authors: Michael J. Domanski, Colin O. Wu, Xin Tian, Ahmed A. Hasan, Xiaoyang Ma, Yi Huang, Rui Miao, Jared P. Reis, Sejong Bae, Anwar Husain, David R. Jacobs, Norrina B. Allen, Mei-Ling T. Lee, Charles C. Hong, Michael E. Farkouh, Donald M. Lloyd-Jones, Valentin Fuster
Journal: Journal of the American College of Cardiology (2023)
Annals On Call - Exercise for Knee Osteoarthritis: Is More Better?
Authors: Robert M. Centor, Patricia L. Perez
Journal: Annals of Internal Medicine (2023)

Web ExclusivesMarch 2023Annals On Call - Exercise for Knee Osteoarthritis: Is More Better?FREERobert M. Centor, MD and Patricia L. Perez, PT, DScPTRobert M. Centor, MDHuntsville Regional Medical Campus, University of Alabama Birmingham School of Medicine, Birmingham, Alabama (R.M.C.)Search for more papers by this author and Patricia L. Perez, PT, DScPTUniversity of Alabama at Birmingham, Birmingham, Alabama (P.L.P.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/A22-0006 CME/MOC SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In this episode of Annals On Call, Dr. Centor discusses the role of exercise in the treatment of knee osteoarthritis with Dr. Patricia Perez.Annals articles discussed include...High- Versus Low-Dose Exercise Therapy for Knee Osteoarthritis. A Randomized Controlled Multicenter Trial: https://www.acpjournals.org/doi/10.7326/M22-2348Effectiveness of an Unsupervised Online Yoga Program on Pain and Function in People With Knee Osteoarthritis. A Randomized Clinical Trial: https://www.acpjournals.org/doi/10.7326/M22-1761About Annals On CallAnnals On Call focuses on a clinically influential article published in Annals of Internal Medicine. Dr. Robert Centor shares his own perspective on the material and interviews topic area experts to discuss, debate, and share diverse insights about patient care and health care delivery.For more information on Annals On Call and for more episodes, visit go.annals.org/OnCall. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Huntsville Regional Medical Campus, University of Alabama Birmingham School of Medicine, Birmingham, Alabama (R.M.C.)University of Alabama at Birmingham, Birmingham, Alabama (P.L.P.)Disclosures: All relevant financial relationships have been mitigated. Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=A22-0006.Editors' Disclosures: The editors have no relevant financial relationships to disclose. Individual forms may be viewed at www.annals.org/editorsdisclosures. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEffectiveness of an Unsupervised Online Yoga Program on Pain and Function in People With Knee Osteoarthritis Kim L. Bennell , Sarah Schwartz , Pek Ling Teo , Stephanie Hawkins , Dave Mackenzie , Fiona McManus , Karen E. Lamb , Alexander J. Kimp , Ben Metcalf , David J. Hunter , and Rana S. Hinman High- Versus Low-Dose Exercise Therapy for Knee Osteoarthritis Tom Arild Torstensen , Håvard Østerås , Riccardo LoMartire , Georg Mørtvedt Rugelbak , Wilhelmus Johannes Andreas Grooten , and Björn Olov Äng Metrics Current IssueMarch 2023Volume 176, Issue 3 ePublished: 21 March 2023 Issue Published: March 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.Loading ...
Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update
Authors: Robert Reinhard
Journal: Annals of Internal Medicine (2023)

LettersMarch 2023Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 UpdateRobert Reinhard, MARobert Reinhard, MASan Francisco, CaliforniaAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L22-0488 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR: Thank you for publishing DeTora and colleagues' helpful revised Good Publication Practice (GPP) guidelines (1). In light of the principles for transparency and mention of principles for inclusivity, a concerted effort to include patient or research participant representatives and advocates among the experts assembled to draft the guidelines themselves would be a welcome development. The Methods section and information in the Supplement of this article suggest that this was not done. Please add these essential perspectives in GPP guideline development.Reference1. DeTora LM, Toroser D, Sykes A, et al. Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2022;175:1298-304. [PMID: 36037471] doi:10.7326/M22-1460 LinkGoogle Scholar Author, Article, and Disclosure InformationAuthors: Robert Reinhard, MAAffiliations: San Francisco, CaliforniaDisclosures: Authors have reported no disclosures of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L22-0488. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoGood Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update Lisa M. DeTora , Dikran Toroser , Angela Sykes , Christine Vanderlinden , Fiona J. Plunkett , Trevor Lane , Eline Hanekamp , Laura Dormer , Faith DiBiasi , Dan Bridges , Lise Baltzer , and Leslie Citrome Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update Farah Asif Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update Lisa M. DeTora , Trevor Lane , Angela Sykes , Faith DiBiasi , Dikran Toroser , Leslie Citrome Metrics March 2023Volume 176, Issue 3KeywordsClinical trialsDisclosureResearch ethicsResearch reporting guidelines ePublished: 21 March 2023 Issue Published: March 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...